Last reviewed · How we verify
CB-839 and low dose dexamethasone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CB-839 and low dose dexamethasone (CB-839 and low dose dexamethasone) — Calithera Biosciences, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CB-839 and low dose dexamethasone TARGET | CB-839 and low dose dexamethasone | Calithera Biosciences, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CB-839 and low dose dexamethasone CI watch — RSS
- CB-839 and low dose dexamethasone CI watch — Atom
- CB-839 and low dose dexamethasone CI watch — JSON
- CB-839 and low dose dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). CB-839 and low dose dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/cb-839-and-low-dose-dexamethasone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab